A5025567907- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- BRCA gene mutations in cancer
- Cervical Cancer and HPV Research
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Advances in Oncology and Radiotherapy
- Cardiac, Anesthesia and Surgical Outcomes
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Cancer-related Molecular Pathways
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Colorectal and Anal Carcinomas
- HER2/EGFR in Cancer Research
- Hormonal Regulation and Hypertension
- Endometriosis Research and Treatment
- Cancer Mechanisms and Therapy
- Ethics in Clinical Research
- Angiogenesis and VEGF in Cancer
European Institute of Oncology
2010-2025
University of Milan
2012-2025
University of Milano-Bicocca
2013-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2024
University of Pittsburgh
2022
Corcept Therapeutics (United States)
2022
Agostino Gemelli University Polyclinic
2022
University of Chicago
2022
Vall d'Hebron Hospital Universitari
2022
KU Leuven
2022
The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy or without bevacizumab in patients persistent, recurrent, metastatic cervical cancer. Treatment effects patient subgroups study population are unknown.
<h3>Objective</h3> To evaluate tiragolumab (anti-TIGIT) and atezolizumab (anti-PD-L1) as second- or third-line therapy for PD-L1-positive persistent/recurrent cervical cancer. <h3>Methods</h3> In the open-label, non-comparative, randomized phase II SKYSCRAPER-04 trial (NCT04300647), patients with (SP263 tumor area positivity ≥5%) recurrent/persistent cancer after 1–2 chemotherapy lines (≥1 platinum-based) were 3:1 to 1200 mg with/without 600 every 3 weeks until disease progression...
Clinical trials are slow and costly, built around the research centers that study local participants. Building clinical patients in their homes community through remote visits monitoring could enhance recruitment increase convenience for This evaluated different trial settings, a decentralized arm via telemedicine center (virtual conduct), conventional health clinic (onsite conduct) mixed model arm. Acute low-back pain (20-65 years) were recruited to this non-interventional Switzerland. The...
Objective The single-arm, phase II SORAYA trial ( NCT04296890 ) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate 32.4% (95% CI, 23.6 to 42.2). Here we report final results for overall survival and post hoc rates subgroups by sequence number prior therapies. Methods Eligible patients had high-grade serous high FRα expression one three therapies (prior...
LBA5503 Background: Pazopanib is an oral, multikinase inhibitor of VEGFR-1, -2, -3, PDGFR-α and -β, c-Kit. Preclinical clinical studies support VEGF(R) PDGF(R) as targets for AEOC treatment. This study evaluated the efficacy, safety, tolerability pazopanib maintenance therapy in patients who have not progressed after first-line chemotherapy AEOC. Methods: Patients with histologically confirmed AEOC, FIGO II-IV, no evidence progression surgery ≥ 5 cycles platinum-taxane were randomized 1:1 to...
5512 Background: SORAYA is a global single arm phase 3 study evaluating MIRV in patients (pts) with FRα high platinum-resistant ovarian cancer (PROC). an antibody drug conjugate comprising FRα-binding antibody, cleavable linker, and maytansinoid DM4, potent tubulin-targeting agent. In this study, demonstrated activity broad population of PROC, regardless number prior lines therapy or PARPi (Matulonis, SGO 2022). Here we describe details response to treatment important for clinical decision...
5500 Background: The first interim analysis of KEYNOTE-826 (NCT03635567) showed that first-line pembrolizumab (pembro) + chemotherapy (chemo) provided statistically significant and clinically meaningful improvements in OS PFS vs placebo (pbo) chemo patients (pts) with recurrent, persistent, or metastatic cervical cancer across all prespecified populations (PD-L1 combined positive score [CPS] ≥1, all-comer, CPS ≥10). Here, we present the protocol-specified final results KEYNOTE-826. Methods:...
(Abstracted from Lancet Oncol 2023;24:468–482) An estimated 660,000 new cases of cervical cancer were reported globally in 2022, with 350,000 deaths attributable to the disease. Eternal beam radiotherapy concurrent chemotherapy and subsequent brachytherapy is current standard care, few advances have been made recent years increase effectiveness treatments for cancer.
Maintenance olaparib demonstrated clinical activity for progression-free survival in patients without a germline BRCA1 and/or BRCA2 mutation (non-gBRCAm) who had platinum-sensitive relapsed ovarian cancer the phase IIIb, open-label, single-arm, non-comparator, international OPINION trial (NCT03402841). We report final overall (OS; secondary endpoint), prespecified endpoint updates and ad hoc OS analysis by homologous recombination deficiency (HRD) somatic BRCAm (sBRCAm) status. Patients with...
The annual recurrence risk model (ARRM), developed by the Surveillance in Cervical Cancer consortium and endorsed European Society of Gynecological Oncology, predicts cervical cancer recurrence. However, it lacks an external validation, which we aimed to address current retrospective study. We included patients with pathology confirmed T1a T2b cancers who underwent radical surgery at Institute Milan from January 2010 December 2022. Using ARRM calculator, were assigned a score 0 100 points,...
Abstract Background The open-label, single-arm, multicentre ORZORA trial (NCT02476968) evaluated maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) a germline (g) or somatic (s) BRCA1 and/or BRCA2 mutation (BRCAm) non-BRCA homologous recombination repair (non-BRCA HRRm). Methods Patients were response to platinum-based chemotherapy after ≥2 prior lines of treatment and underwent prospective central screening for tumour BRCA status, then gBRCAm testing...
3102 Background: EZH2 inhibition antitumor activity occurs through various mechanistic pathways in multiple tumor types, including via synthetic lethality advanced ARID1A -mutated ovarian clear cell carcinoma (OCCC) and endometrial (EC). Oral, next-generation, dual EZH2/EZH1 inhibitor tulmimetostat is Phase II evaluation disease cohorts (NCT04104776; Oaknin et al. ASCO 2024, ESMO 2024). We report updated efficacy safety data from the OCCC/EC cohorts, dose optimization expansion arms....
The first version of ENGOT's Requirements for Trials Between Academic Groups and Industry Partners in Europe was published 2010. This update integrates the experiences made by ENGOT network cooperative group studies while performing, analyzing, publishing -among others - three large phase III trials. Furthermore, progress European legislation its impact on clinical have been considered this process.
A good educational climate/environment in the workplace is essential for developing high-quality medical (sub)specialists. These data are lacking gynecological oncology training.This study aims to evaluate climate training throughout Europe and factors affecting it.A Web-based anonymous survey sent ENYGO (European Network of Young Gynecological Oncologists) members/trainees assess training. This included sociodemographic information, details regarding posts, a 50-item validated Dutch...